These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 12435858)

  • 1. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.
    Rait AS; Pirollo KF; Xiang L; Ulick D; Chang EH
    Mol Med; 2002 Aug; 8(8):475-86. PubMed ID: 12435858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents.
    Rait AS; Pirollo KF; Ulick D; Cullen K; Chang EH
    Ann N Y Acad Sci; 2003 Dec; 1002():78-89. PubMed ID: 14751825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
    Xu L; Tang WH; Huang CC; Alexander W; Xiang LM; Pirollo KF; Rait A; Chang EH
    Mol Med; 2001 Oct; 7(10):723-34. PubMed ID: 11713371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.
    Ueno NT; Yu D; Hung MC
    Oncogene; 1997 Aug; 15(8):953-60. PubMed ID: 9285690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.
    Waterhouse DN; Gelmon KA; Masin D; Bally MB
    J Exp Ther Oncol; 2003; 3(5):261-71. PubMed ID: 14696623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
    Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
    Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
    Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
    Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment.
    Jhaveri MS; Rait AS; Chung KN; Trepel JB; Chang EH
    Mol Cancer Ther; 2004 Dec; 3(12):1505-12. PubMed ID: 15634643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells.
    Witters LM; Santala SM; Engle L; Chinchilli V; Lipton A
    Am J Clin Oncol; 2003 Feb; 26(1):50-4. PubMed ID: 12576925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
    Chiu SJ; Marcucci G; Lee RJ
    Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
    Hu Q; Bally MB; Madden TD
    Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.
    Li S; Deshmukh HM; Huang L
    Pharm Res; 1998 Oct; 15(10):1540-5. PubMed ID: 9794495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimal effects of liposome on antisense oligodeoxynucleotides uptake by mouse breast cancer TM40D cells and the effects of antisense oligodeoxynucleotides targeting c-erbB-2 on cell proliferation and apoptosis].
    Liu XA; Fan P; Wu ZY
    Zhonghua Wai Ke Za Zhi; 2004 Jul; 42(13):802-5. PubMed ID: 15363300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.